CF
OCUL icon

Cantor Fitzgerald’s Ocular Therapeutix OCUL Stock Holding History

Cantor Fitzgerald’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-201,865
Closed -$2.36M – 321
2025
Q3 		$2.36M Buy
+201,865
New +$2.41M 0.02% 149

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cantor Fitzgerald's OCUL Position: Q4 2025 in Review

Cantor Fitzgerald sold out of Ocular Therapeutix (OCUL) in Q4 2025, closing a stake of 201,865 shares — an estimated $2.36M sold.

Cantor Fitzgerald first reported a position in OCUL in Q3 2025 and held it in 1 quarter. The position peaked at $2.36M in Q3 2025. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

  • Cantor Fitzgerald reported no remaining Ocular Therapeutix position as of Q4 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 201,865 Ocular Therapeutix shares in Q4 2025, an estimated $2.36M.
  • Cantor Fitzgerald first reported a position in Ocular Therapeutix in Q3 2025 and held it in 1 quarter.
  • Cantor Fitzgerald's Ocular Therapeutix position peaked at $2.36M in Q3 2025.
  • 249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.